세계의 인플루엔자 백신 시장 보고서 : 백신 유형, 기술, 연령층, 투여 경로, 지역별(2024-2032년)

The global influenza vaccine market size reached US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032. The launch of numerous favorable initiatives by government bodies promoting vaccination programs, the rising prevalence of influenza and seasonal outbreaks, and the introduction of more effective and broadly protective influenza vaccines are some of the key factors driving the market globally.

Global Influenza Vaccine Market Analysis:

Major Market Drivers: One of the primary influenza vaccine market drivers is the growing initiatives launched by healthcare organizations to increase public awareness regarding the importance of influenza vaccinations. These agencies are also organizing health education campaigns, which are propelling the market growth. Furthermore, government bodies across countries are providing subsidies and free vaccinations for priority age groups, such as elderly individuals, healthcare workers, and children, which, in turn, is improving access to vaccines.

Key Market Trends: One of the primary influenza vaccine market trends is the rising investment by key players in the production and distribution of quadrivalent vaccines. In addition, the introduction of novel technologies, such as recombinant and cell-based approaches, is expected to bolster the influenza vaccine market demand over the forecasted period.

Geographical Trend: According to the report, North America holds the largest regional market for influenza vaccines. The increasing focus of healthcare authorities to prioritize vaccination programs and campaigns is driving the regional market. Furthermore, well-established healthcare infrastructures in North America and extensive investments in R&D activities are also acting as significant growth-inducing factors.

Competitive Landscape: Some of the prominent companies in the influenza vaccine market include Abbott Laboratories, AstraZeneca plc, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and SINOVAC, among many others.

Challenges and Opportunities: One of the key challenges in the influenza vaccine market outlook is complex regulatory approval processes that can negatively impact the distribution of vaccines. In addition to this, the inflating need for scaling up production and ensuring efficacy and safety across various age groups is further hindering the global market. However, the rising efforts from government bodies and public healthcare organizations to ensure that influenza vaccines are accessible, effective, and accepted by individuals will continue to augment the influenza vaccine market growth in the coming years.

Global Influenza Vaccine Market Trends:

Increasing Seasonal Influenza Outbreaks and Pandemics

The rising cases of seasonal influenza are elevating the hospitalization rates. For example, according to the Statista Research report, published on December 6, 2023, there were 31 million cases of influenza in the United States during the 2022-2023 flu season. Moreover, there were 4,977 number of deaths caused by influenza during the 2021-2022 flu season. In addition to this, a large part of the population in the United States failed to get vaccinated. In 2021-2022, only 37 % of those aged 18 to 49 years received a flu vaccination, which was much lower as compared to children and the elderly. As such, the elevating focus among healthcare organizations on highlighting the importance of influenza vaccinations is bolstering the market growth. For instance, in February 2023, the World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2023-2024 influenza season. The announcement was made at an information session at the end of a 4-day meeting on the composition of influenza virus vaccines.

The Rising Awareness Towards Influenza Vaccination

The growing prevalence of seasonal influenza is primarily bolstering the market growth. For example, the global flu data that was published in February 2022 mentioned that an estimated 1 billion individuals worldwide were infected by seasonal influenza. In line with this, the report also stated that out of those 1 billion, about 3 to 5 million people had a severe case of flu every year. Furthermore, according to the data published by WHO in December 2022, 5%-15% of the population was affected by influenza in the European region. Similarly, the Plos One Journal article published in July 2021 mentioned that approximately 5%-10% and 20%-30% of new cases of influenza infections occurred among children and adults annually. The elevating cases of the influenza virus are increasing awareness among individuals towards influenza vaccination, which is providing a positive outlook to the overall market growth. Besides this, healthcare organizations are launching campaigns to provide information regarding the benefits of immunization, thereby driving the demand for influenza vaccines. For example, a healthcare survey conducted in June 2022 by Sanofi reported that pharmacists and physicians recommended Centers for Disease Control and Prevention (CDC) to provide vaccines like Fluzone high-dose quadrivalent, for people who're 65 and older, for the treatment of influenza. The growing inclination among individuals of all age groups will continue to propel the influenza vaccine market share over the forecasted period.

The Growing Support from Government Bodies

Government bodies across the globe are collaborating with key companies to support R&D activities related to the development of influenza vaccines. As per the influenza vaccine market statistics, in September 2021, the Centers for Disease Control and Prevention (CDC) entered a broad inter-agency partnership coordinated by the Biomedical Advanced Research and Development Authority (BARDA) that supported the advanced development of novel influenza vaccines. Furthermore, government authorities are enhancing and easing the process of regulatory approvals, which is positively influencing the influenza vaccine market growth. For example, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the Fluarix, which is a quadrivalent vaccine. In line with this, the government is also investing in clinical trials and R&D activities related to the development of influenza vaccinations. For instance, in March 2022, the government bodies in Australia invested more than US$ 100 Million in the seasonal influenza vaccine to protect individuals at risk. Additionally, major healthcare companies are investing extensively in the introduction of advanced therapy in the form of vaccines. This, in turn, is bolstering the future of influenza vaccine market.

Influenza Vaccine Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global influenza vaccine market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on vaccine type, technology, age group and route of administration.

Breakup by Vaccine Type:

Quadrivalent

Trivalent

Quadrivalent represents the most popular type of influenza vaccine

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes quadrivalent and trivalent. According to the report, quadrivalent represented the largest segment.

Quadrivalent influenza vaccines are specifically designed to protect against four flu viruses, namely two influenza A viruses and two influenza B viruses. The quadrivalent segment holds a significant share of the influenza vaccine market, owing to its efficacy against viral infections, cost-effectiveness, and easy availability in clinics and hospitals. In addition to this, the fast product approvals for the quadrivalent type of vaccine are also fueling the market growth. For example, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the Fluarix, which is a quadrivalent vaccine. The Fluarix quadrivalent vaccine provides active immunization to prevent disease caused by the influenza A subtype virus and type B virus. Furthermore, key companies are investing in vaccine facilities to elevate the production processes, thereby driving the global market for influenza vaccine. For example, in April 2021, Sanofi invested over € 600 million to build a new vaccine facility in Toronto to increase its supply of influenza vaccines in the United States, Canada, and Europe. The new facility developed quadrivalent influenza vaccines and served its customers with effective vaccinations.

Breakup by Technology:

Egg-based

Cell-based

Egg-based holds the largest share in the market

A detailed breakup and analysis of the market based on the technology has also been provided in the report. This includes egg-based and cell-based. According to the report, egg-based accounted for the largest market share.

Egg-based technology refers to one of the conventional methods utilized for vaccine production, wherein the influenza virus strains are grown in chicken eggs before being processed and harvested for vaccine formulation. Moreover, the egg-based method has been extensively adopted, owing to its established safety, scalability, cost-effectiveness, etc. For example, in February 2024, the WHO announced recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. The egg-based vaccines that are recommended include an A/Victoria/4897/2022 (H1N1)pdm09-like virus, an A/Thailand/8/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Breakup by Age Group:

Pediatric

Adult

Pediatric dominates the market

A detailed breakup and analysis of the market based on the age group has also been provided in the report. This includes pediatric and adult. According to the report, pediatric accounted for the largest market share.

Pediatric vaccines are specifically formulated to enhance the immune systems of children, especially those under the age of five, who are more susceptible to severe flu-related complications. These vaccinations aid in ensuring adequate protection against the disease. Consequently, healthcare providers, government bodies, and parents are recognizing the importance of pediatric influenza vaccination, leading to the escalating demand for pediatric flu vaccines.

Breakup by Route of Administration:

Injection

Nasal Spray

A detailed breakup and analysis of the market based on the route of administration has also been provided in the report. This includes injection and nasal spray.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest regional market for influenza vaccines.

In North America, the growing prevalence of the influenza virus is propelling the regional market. According to the CDC data, nearly 150,865 influenza-positive cases were reported in December 2022, among which 149,704 cases were influenza A and 1,61 influenza B virus types. In line with this, in December 2022, the Public Health Agency of Canada mentioned that nearly 34,413 influenza cases were reported in Canada from August 2022 to December 2022. Such increased occurrence of influenza cases among the population across North America is expected to drive the need for influenza vaccines. For instance, in June 2021, NIH launched the clinical trials of FluMos-v1, a vaccine candidate in the United States. This vaccine stimulates antibodies against multiple influenza virus strains by displaying part of the influenza virus proteins.

Competitive Landscape:

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the influenza vaccine top companies are listed below:

Abbott Laboratories

AstraZeneca plc

CSL Limited

Daiichi Sankyo Company Limited

Emergent BioSolutions Inc.

F. Hoffmann-La Roche AG

Gamma Vaccines Pty Ltd

GlaxoSmithKline plc

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Sanofi

SINOVAC

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Influenza Vaccine Market News:

March 2024: Osivax, a biopharmaceutical company, announced that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, which was a broad-spectrum influenza A vaccine and quadrivalent influenza vaccines (QIVs) candidate.

March 2024: Ahmedabad-based pharmaceutical company, Cadila Pharmaceuticals, announced the launch of a new influenza vaccine called Cadiflu Tetra.

February 2024: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of two vaccines for active immunization against the H5N1 subtype of the influenza A virus, which causes avian influenza or bird flu.

October 2023: Mylab in Pune and Serum Institute of India have launched Nasovac S4, India's first needle-free nasal influenza vaccine.

Key Questions Answered in This Report

• 1. What was the size of the global influenza vaccine market in 2023?
• 2. What is the expected growth rate of the global influenza vaccine market during 2024-2032?
• 3. What are the key factors driving the global influenza vaccine market?
• 4. What are the key factors driving the global influenza vaccine market?
• 5. What has been the impact of COVID-19 on the global influenza vaccine market?
• 6. What is the breakup of the global influenza vaccine market based on the vaccine type?
• 7. What is the breakup of the global influenza vaccine market based on the technology?
• 8. What is the breakup of the global influenza vaccine market based on the age group?
• 9. What are the key regions in the global influenza vaccine market?
• 10. Who are the key players/companies in the global influenza vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Influenza Vaccine Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Vaccine Type

• 6.1 Quadrivalent
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Trivalent
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Egg-based
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Cell-based
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Age Group

• 8.1 Pediatric
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Adult
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

• 9.1 Injection
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Nasal Spray
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 AstraZeneca plc
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 CSL Limited
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Daiichi Sankyo Company Limited
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Emergent BioSolutions Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 F. Hoffmann-La Roche AG
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 SWOT Analysis
  • 15.3.7 Gamma Vaccines Pty Ltd
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 GlaxoSmithKline plc
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Merck & Co. Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Novartis AG
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Pfizer Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Sanofi
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 SINOVAC
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio
    • 15.3.13.3 Financials